Actualités & Événements

Raise awareness to protect !

Because testicular and prostate cancers are among the most common in men, it is important to inform our employees.

For this third edition of Movember, they have also adopted the mustache !

Beyond the decorations and cake surprises in the colors of the event, this moment allows us to highlight the screening. It can save lives.

If cancer is detected early, chances of cure are high and treatments are less burdensome.

In October, our team took part in the run named « La Foulée de la vie » in Trets. This event raises funds for the Paoli Calmettes Institute, a cancer center in Marseille.

Because life is not always rosy... 🎗

Because breast cancer is the most common among women, and cervical cancer the 4th...

It's important to inform our employees so that they can be on alert and adopt the right reflexes in case of doubt.

First day at EANM in Vienna for our iMiGiNE team. Learn more about our iMiGiNE product portfolio :

- iMiTRACE: the 12 MeV Cyclotron to produce up to 4 PET radioisotopes
 
- iMiLAB: the automated radiochemistry using microfluidics
 
- iMiDEV: the microfluidic synthesizer to perform R&D

And what coming next ?  

Meet us booth 203 - Hall X2 

Our team participated in the International Conference and Exhibition on Non-Destructive Testing in India from August 24 to 26. A booth share with First Source and Cyxplus. A very interesting congress to present the range of linear accelerator Oriatron.

After promising results obtained on the iMiDEV microfluidic synthesizer, Eckert & Ziegler, Pentixapharm and PMB announce their partnership on an innovative project. The three companies have signed a letter of intent demonstrating their willingness to collaborate together in order to offer a cutting-edge solution for the synthesis of radiopharmaceuticals for the therapy.

We are proud and honored to introduce the FLASHKNiFE Consortium, supported by the European Institute of Innovation & Technology for Health (EIT Health).

We are proud to have partnered with Nancyclotep and provided their state-of-the-art technical platform with an iMiTRACE cyclotron and an iMiLAB radiochemistry. These systems will allow us to promote the research and development of new molecules of clinical interest, specifically for theranostics and VIRT. 

An automated radiopharmaceutical production system iMiGiNE has been installed in Frederic Joliot Hospital (CEA) in Orsay, France and commissioned in December 2020. This disruptive system will revolutionize the radiopharmaceutical production, access and distribution. iMiGiNE will allow clinical centers to directly access disease-specific radiopharmaceuticals, otherwise rarely available, and take a first step towards personalized molecular imaging.

Discover our 3D Virtual Booth! Exclusive content, navigation around our iMiGiNE system (cyclotron & radiochemistry) and new advances on our iMiLAB radiochemistry R&D system, for radiopharmaceutical development. 

We're ready for a chat! 

https://imigine-pmb.exhibitcast.net/pmb/

We are hosting an exclusive event on FLASH radiotherapy and FLASHKNiFE, with testimonials from experts in the field. Join us for this virtual experience and give us your thoughts on FLASH radiation therapy, current research and possible future treatments. 

https://pmb-alcen.hubspotpagebuilder.com/join-us-for-an-exclusive-event-on-flash-radiotherapy

We are excited to be participating in the ASTRO for the first time! Use the code INVITE166 to register! 

PMB, a subsidiary of the ALCEN group, is proud to announce the launch of FLASHKNiFE, the FLASH radiotherapy system dedicated to clinical trials.

PMB is proud to have partnered with the University Hospital of Lausanne (CHUV) for the first treatment of a human patient with FLASH-radiotherapy, in Switzerland. A 75-year-old patient with multiple skin tumors, was treated using the ORIATRON eRT6, a LINAC specifically engineered to safely accelerate electrons in a “FLASH” mode.